ISO 10993-17:2023

International Standard   Current Edition · Approved on 13 September 2023

Biological evaluation of medical devices — Part 17: Toxicological risk assessment of medical device constituents

ISO 10993-17:2023 Files

English 65 Pages
Current Edition
BHD 92.11

ISO 10993-17:2023 Scope

This document specifies the process and requirements for the toxicological risk assessment of medical device constituents. The methods and criteria used to assess whether exposure to a constituent is without appreciable harm are also specified. The toxicological risk assessment can be part of the biological evaluation of the final product, as described in ISO 10993-1.

The process described in this document applies to chemical characterization information obtained in line with ISO 10993-18. When a toxicological risk assessment of either the compositional information or analytical chemistry data (e.g. extractable data or leachable data) are required to determine whether the toxicological risks related to the constituents are negligible or tolerable.

The process described in this document is not intended to apply to circumstances where the toxicological risk has been estimated by other means, such as:

—    constituents, excluding cohort of concern or excluded chemicals, that are present in or extracted from a medical device at an amount representative of patient exposure below a relevant, toxicologically-based reporting threshold (see applicable requirements in ISO 10993-18:2020, Annex E and ISO/TS 21726);

—    a new or changed medical device for which chemical or biological equivalence has been established with an existing biocompatible or clinically established medical device (see applicable requirements in ISO 10993-18:2020, Annex C).

The process described in this document is also not applicable to:

—    medical device constituents that do not contact the body (e.g. in vitro diagnostics);

—    biological risks associated with physical interactions of the medical device with the body (i.e. application of mechanical forces, energy or surface morphology, etc.), provided that the chemical exposure is not changed;

—    active pharmaceutical ingredients of device-drug combination products or biologic components of device-biologic combination products as additional regulatory considerations can apply;

—    exposure to a particular constituent that arises from sources other than the device, such as food, water or air.

Best Sellers

GSO 150-2:2013
 
Gulf Standard
Expiration dates for food products - Part 2 : Voluntary expiration dates
BH GSO 150-2:2015
GSO 150-2:2013 
Bahraini Standard
Expiration dates for food products - Part 2 : Voluntary expiration dates
GSO 9:2022
 
Gulf Technical Regulation
Labeling of prepackaged food stuffs
BH GSO 9:2023
GSO 9:2022 
Bahraini Technical Regulation
Labeling of prepackaged food stuffs

Recently Published

ISO/IEC/IEEE 24748-8:2026
 
International Standard
Systems and software engineering — Life cycle management — Part 8: Technical reviews and audits on defence programs
ISO 24304:2026
 
International Standard
Textiles — Determination of the aerobic biodegradation of textile materials in seawater
ISO 19014-5:2026
 
International Standard
Earth-moving machinery — Functional safety — Part 5: Tables of performance levels
ISO 19014-1:2026
 
International Standard
Earth-moving machinery — Functional safety — Part 1: Methodology to determine safety-related parts of the control system and performance requirements